What the Research Says
L-Lysine is a conditionally essential amino acid known for its antiviral properties against herpes simplex virus (HSV). Griffith et al. (1987) demonstrated that 3 g/day of L-lysine significantly reduced HSV recurrence in a randomized controlled trial, with the mechanism involving competitive inhibition of arginine, which HSV requires for replication. Beyond antiviral effects, lysine supports collagen formation and calcium metabolism, as shown by Civitelli et al. (1992).
Recent studies highlight additional benefits and safety profiles. Hayamizu et al. (2020) conducted a systematic review of 71 studies (3357 participants) and found no significant risk of adverse effects from L-lysine supplementation, with minor gastrointestinal symptoms reported but not statistically significant. Similarly, Hayamizu et al. (2019) reviewed 71 studies on oral lysine intake and concluded that doses up to 6000 mg/day are safe.
Emerging research also suggests potential benefits in mental health conditions like schizophrenia. Fornaro et al. (2025) conducted a systematic review and network meta-analysis of 50 studies (n=2384) and found that L-lysine, along with other nutraceuticals, improved total symptomatology in stable schizophrenia patients compared to placebo. However, evidence quality remains moderate due to older study designs and relatively small sample sizes.
In summary, L-Lysine is effective for reducing HSV recurrence, supports collagen and calcium metabolism, and has a favorable safety profile at recommended doses. Emerging research also suggests potential benefits in mental health conditions like schizophrenia.




